Tag: hypertension

Articles

• Influence of BMI, metabolic syndrome and diabetes on TN prognosis

News

10/27/11

The beta blocker propranolol increases the effectiveness of Taxol

Studies

• Association Between Metabolic Syndrome and Immunohistochemical Profile at Breast Cancer Diagnosis in Postmenopausal Women Cite
  Motoki AH, Buttros DA, Gaspar AL, Almeida-Filho BS, Carvalho-Pessoa E, Vespoli HD, et al. Association Between Metabolic Syndrome and Immunohistochemical Profile at Breast Cancer Diagnosis in Postmenopausal Women. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.07.009
• Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer Cite
  Lorona NC, Cook LS, Tang MC, Hill DA, Wiggins CL, Li CI. Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer. Cancer Causes & Control. Springer Science and Business Media LLC; 2021; 10.1007/s10552-021-01485-3
• Multimorbidity clusters among long‐term breast cancer survivors in Spain: Results of the SURBCAN study Cite
  Jansana A, Poblador‐Plou B, Gimeno‐Miguel A, Lanzuela M, Prados‐Torres A, Domingo L, et al. Multimorbidity clusters among long‐term breast cancer survivors in Spain: Results of the SURBCAN study. International Journal of Cancer. Wiley; 2021; 10.1002/ijc.33736
• The Hypertension Related Gene G-Protein Coupled Receptor Kinase 4 Contributes to Breast Cancer Proliferation Cite
  Yue W, Tran HT, Wang J, Schiermeyer K, Gildea JJ, Xu P, et al. The Hypertension Related Gene G-Protein Coupled Receptor Kinase 4 Contributes to Breast Cancer Proliferation. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2021; 15:117822342110157 10.1177/11782234211015753
• Comorbidities and the risk of cardiovascular disease mortality among racially diverse patients with breast cancer Cite
  Connor AE, Schmaltz CL, Jackson‐Thompson J, Visvanathan K. Comorbidities and the risk of cardiovascular disease mortality among racially diverse patients with breast cancer. Cancer. Wiley; 2021; 10.1002/cncr.33530
• Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis Cite
  Dong S, Wang Z, Shen K, Chen X. Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis. Frontiers in Oncology. Frontiers Media SA; 2021; 11 10.3389/fonc.2021.629666
• Beta-blockers use and risk of breast cancer in women with hypertension Cite
  Zheng G, Sundquist J, Sundquist K, Ji J. Beta-blockers use and risk of breast cancer in women with hypertension. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2021;:cebp.1599.2020 10.1158/1055-9965.epi-20-1599
• Postoperative Survival of Breast Cancer Patients Aged 85 Years or Older: A Retrospective Study Cite
  Enomoto K, Fukumoto S, Hara K, Mori S, Hara Y, Tada K. Postoperative Survival of Breast Cancer Patients Aged 85 Years or Older: A Retrospective Study. Research Square; 2021; 10.21203/rs.3.rs-141173/v1
• Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population? Cite
  Kennard K, Buckley ME, Sizer LM, Larson S, Carter WB, Frazier TG, et al. Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-020-06034-1
• Plasma Magnesium Concentrations and Risk of Incident Cancer in Adults with Hypertension: A Nested Case-Control Study Cite
  Lin T, Bi C, Song Y, Guo H, Liu L, Zhou Z, et al. Plasma Magnesium Concentrations and Risk of Incident Cancer in Adults with Hypertension: A Nested Case-Control Study. Annals of Nutrition and Metabolism. S. Karger AG; 2020;:1-9 10.1159/000510214
• Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer Cite
  Nyrop KA, Damone EM, Deal AM, Carey LA, Lorentsen M, Shachar SS, et al. Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer. Cancer. Wiley; 2020; 10.1002/cncr.33288
• Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival—A Nationwide Cohort Study from Finland Cite
  Santala EE, Murto MO, Artama M, Pukkala E, Visvanathan K, Murtola TJ. Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival—A Nationwide Cohort Study from Finland. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2020; 29:2376-2382 10.1158/1055-9965.epi-20-0711
• Dietary Approaches to Stop Hypertension (DASH) diets and breast cancer among women: a case control study Cite
  Heidari Z, Mohammadi E, Aghamohammadi V, Jalali S, Rezazadeh A, Sedaghat F, et al. Dietary Approaches to Stop Hypertension (DASH) diets and breast cancer among women: a case control study. BMC Cancer. Springer Science and Business Media LLC; 2020; 20 10.1186/s12885-020-07209-1
• Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study Cite
  Lofterød T, Frydenberg H, Flote V, Eggen AE, McTiernan A, Mortensen ES, et al. Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 182:215-227 10.1007/s10549-020-05679-2
• The Association between Hypertension and Race/Ethnicity among Breast Cancer Survivors Cite
  Williams MS, Beech BM, Griffith DM, Jr. Thorpe RJ. The Association between Hypertension and Race/Ethnicity among Breast Cancer Survivors. Journal of Racial and Ethnic Health Disparities. Springer Science and Business Media LLC; 2020; 7:1172-1177 10.1007/s40615-020-00741-7
• Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer Cite
  Takada K, Kashiwagi S, Asano Y, Goto W, Takahashi K, Fujita H, et al. Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2019; 19 10.1186/s12885-019-5828-5
• Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients Cite
  Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC: Cardiovascular Imaging. Elsevier BV; 2018; 11:1084-1093 10.1016/j.jcmg.2018.06.005
• Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women Cite
  Kabat GC, Kim MY, Lee JS, Ho GY, Going SB, Beebe-Dimmer J, et al. Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2017; 26:1730-1735 10.1158/1055-9965.epi-17-0495
• Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Cite
  Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2018; 19:127-138 10.1016/s1470-2045(17)30715-5
• Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study Cite
  Blaes A, Beckwith H, Florea N, Hebbel R, Solovey A, Potter D, et al. Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 166:541-547 10.1007/s10549-017-4447-6
• Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study Cite
  Spera G, Fresco R, Fung H, Dyck J, Pituskin E, Paterson I, et al. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Annals of Oncology. Elsevier BV; 2017; 28:1836-1841 10.1093/annonc/mdx264
• Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy Cite
  Yeo W, Mo FKF, Pang E, Suen JJS, Koh J, Loong HHF, et al. Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy. BMC Women's Health. Springer Science and Business Media LLC; 2017; 17 10.1186/s12905-017-0409-8
• Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study Cite
  Spera G, Fresco R, Fung H, Dyck J, Pituskin E, Paterson I, et al. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Annals of Oncology. Elsevier BV; 2017; 28:1836-1841 10.1093/annonc/mdx264
• The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma Cite
  Coulson R, Liew SH, Connelly AA, Yee NS, Deb S, Kumar B, et al. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget. Impact Journals, LLC; 2017; 8:18640-18656 10.18632/oncotarget.15553
• Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer Cite
  Schairer C, Gadalla SM, Pfeiffer RM, Moore SC, Engels EA. Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2017; 26:862-868 10.1158/1055-9965.epi-16-0647
• Abstract LB-257: The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma Cite
  Coulson RS, Deb S, Ernst M, Allen A, Chand AL. Abstract LB-257: The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Clinical Research (Excluding Clinical Trials). American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-lb-257
• Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer Cite
  Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2712-2720 10.1200/jco.2016.66.8822
• Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake Cite
  Bloomfield HE, Koeller E, Greer N, MacDonald R, Kane R, Wilt TJ. Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake. Annals of Internal Medicine. American College of Physicians; 2016; 165:491 10.7326/m16-0361
• Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women Cite
  Wilson LE, D’Aloisio AA, Sandler DP, Taylor JA. Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women. Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0720-6
• Effect of folic acid supplementation on cancer risk among adults with hypertension in China: A randomized clinical trial Cite
  Qin X, Shen L, Zhang R, Li Y, Wang X, Wang B, et al. Effect of folic acid supplementation on cancer risk among adults with hypertension in China: A randomized clinical trial. International Journal of Cancer. Wiley; 2017; 141:837-847 10.1002/ijc.30094
• Antihypertensive agents and the risk of breast cancer in women aged 55 years and older Cite
  Chang C, Chiang C, Yen C, Wu L, Lin J, Lai M. Antihypertensive agents and the risk of breast cancer in women aged 55 years and older. Journal of Hypertension. Ovid Technologies (Wolters Kluwer Health); 2016; 34:558-566 10.1097/hjh.0000000000000813
• Impact of very low physical activity, BMI, and comorbidities on mortality among breast cancer survivors Cite
  Nelson SH, Marinac CR, Patterson RE, Nechuta SJ, Flatt SW, Caan BJ, et al. Impact of very low physical activity, BMI, and comorbidities on mortality among breast cancer survivors. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:551-557 10.1007/s10549-016-3694-2
• Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer Cite
  Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, et al. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2016; 2:29 10.1001/jamaoncol.2015.3709
• Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer among Women Diagnosed with Estrogen Receptor–Positive Invasive Breast Cancer Cite
  Chen L, Malone KE, Li CI. Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer among Women Diagnosed with Estrogen Receptor–Positive Invasive Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2015; 24:1423-1426 10.1158/1055-9965.epi-15-0547
• Metabolic syndrome and breast cancer prognosis Cite
  Berrino F, Villarini A, Traina A, Bonanni B, Panico S, Mano MP, et al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 147:159-165 10.1007/s10549-014-3076-6
• Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women Cite
  Botteri E, Munzone E, Rotmensz N, Cipolla C, De Giorgi V, Santillo B, et al. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2013; 140:567-575 10.1007/s10549-013-2654-3
• AFRICAN AMERICAN RACE IS A CORRELATE OF HEART FAILURE IN BREAST CANCER SURVIVORS: A STUDY OF 26,347 WOMEN IDENTIFIED WITH BREAST CANCER FROM 1973-2007 Cite
  Valina-Toth AL, Zavodnik T, Seicean S, Plana J, Marwick T. AFRICAN AMERICAN RACE IS A CORRELATE OF HEART FAILURE IN BREAST CANCER SURVIVORS: A STUDY OF 26,347 WOMEN IDENTIFIED WITH BREAST CANCER FROM 1973-2007. Journal of the American College of Cardiology. Elsevier BV; 2013; 61:E580 10.1016/s0735-1097(13)60580-x
• Effects of ALA, EPA and DHA in high-carbohydrate, high-fat diet-induced metabolic syndrome in rats Cite
  Poudyal H, Panchal SK, Ward LC, Brown L. Effects of ALA, EPA and DHA in high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. The Journal of Nutritional Biochemistry. Elsevier BV; 2013; 24:1041-1052 10.1016/j.jnutbio.2012.07.014
• Beta Blockers and Breast Cancer Mortality: A Population- Based Study Cite
  Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta Blockers and Breast Cancer Mortality: A Population- Based Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:2635-2644 10.1200/jco.2010.33.5422
• Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer Cite
  Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, et al. Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:2645-2652 10.1200/jco.2010.33.4441
• Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort Cite
  Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:549-556 10.1007/s10549-011-1505-3
• Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Cite
  Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. Wiley; 2011; 13:1-10 10.1093/eurjhf/hfq213
• The association of metabolic syndrome with triple-negative breast cancer Cite
  Maiti B, Kundranda MN, Spiro TP, Daw HA. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 121:479-483 10.1007/s10549-009-0591-y
• A Longitudinal Study of the Metabolic Syndrome and Risk of Postmenopausal Breast Cancer Cite
  Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, et al. A Longitudinal Study of the Metabolic Syndrome and Risk of Postmenopausal Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:2046-2053 10.1158/1055-9965.epi-09-0235